The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.

The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.

[Anonymous].  1992.  The prognostic implications of low serum CA 125 levels prior to the second-look operation for stage III and IV epithelial ovarian cancer.. Gynecologic oncology. 46(1):29-32.

Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.

Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.

DNA cytometry in postirradiation cervical-vaginal smears.

Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma.

Endometrioid carcinoma of the ovary and endometriosis: the association in postmenopausal women.

Molecular genetic changes in human epithelial ovarian malignancies.

Ovarian cancer screening.

Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.

Immunohistochemical staining for CA-125 in fallopian tube carcinomas.